利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.011 秒)

    Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
    1.
    发明授权
    Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors 失效
    用一氧化氮底物和/或供体治疗骨质疏松症和代谢性骨骼疾病

    公开(公告)号：US6133320A

    公开(公告)日：2000-10-17

    申请号：US177978

    申请日：1998-10-22

    申请人： Chandrasekhar Yallampalli ,  Sunil J. Wimalawansa

    发明人： Chandrasekhar Yallampalli ,  Sunil J. Wimalawansa

    IPC分类号： A61K31/198 ,  A61K31/21 ,  A61K31/295 ,  A61K31/34 ,  A61K31/5377 ,  A61K31/565 ,  A61K45/06 ,  A61K31/155 ,  A61K31/04

    CPC分类号： A61K45/06 ,  A61K31/198 ,  A61K31/21 ,  A61K31/295 ,  A61K31/34 ,  A61K31/5377 ,  A61K31/565

    摘要： Primary and secondary osteoporosis in a female or a male mammal is treated by administering thereto a nitric oxide synthase substrate, a nitric oxide donor or both, optionally; in further combination with one or more of an estrogen, a progestin, an anabolic steroid. Nitric oxide substrate or donor also can be combined with one or more of other medications acting on bone, such as bisphosphonate, calcitonin, fluoride, androgen and other novel therapeutic agents. Either nitric oxide donor or substrate by itself or combination with other medications as described above can be used in both women and men, (preferably human) for prevention and treatment of osteoporosis and other metabolic bone disorders.

    摘要翻译： 通过向其施用一氧化氮合酶底物，一氧化氮供体或两者，任选地处理雌性或雄性哺乳动物的原发性和继发性骨质疏松症; 与雌激素，孕激素，合成代谢类固醇中的一种或多种进一步组合。 一氧化氮底物或供体也可与一种或多种其它作用于骨的药物组合，例如二膦酸盐，降钙素，氟化物，雄激素和其它新型治疗剂。 如上所述，一氧化氮供体或底物本身或与其它药物组合可用于男性和女性（优选人）用于预防和治疗骨质疏松症和其它代谢性骨病。

    Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
    2.
    发明授权
    Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor 失效
    用降钙素基因相关肽，CGRP类似物，孕激素，一氧化氮源和环氧合酶抑制剂治疗或预防先兆子痫和子痫

    公开(公告)号：US5910482A

    公开(公告)日：1999-06-08

    申请号：US619841

    申请日：1996-03-19

    申请人： Chandrasekhar Yallampalli ,  Sunil J. Wimalawansa

    发明人： Chandrasekhar Yallampalli ,  Sunil J. Wimalawansa

    IPC分类号： A61K38/22 ,  A61K45/06 ,  A61K31/04

    CPC分类号： A61K45/06 ,  A61K31/198 ,  A61K31/21 ,  A61K31/405 ,  A61K31/5578 ,  A61K31/57 ,  A61K31/616 ,  A61K38/225

    摘要： The present invention provides a method for counteracting preeclampsia, eclampsia of pregnancy and preterm labor in a pregnant female mammal treated by administering thereto calcitonin gene-related peptide (CGRP) or its analogues including CGRP/adrenomedullin or their peptide or receptor-based analogues, or in combination with a progestin, and with or without a nitric oxide substrate, or a nitric oxide donor or both, optionally in further combination with one or more of a cyclooxygenase inhibitor, a PGI.sub.2 -mimetic, a thromboxane (TXA.sub.2) inhibitor, a compound possessing TXA.sub.2 -agonistic, and TXA.sub.2 -inhibiting properties, a compound possessing TXA.sub.2 -antagonistic and PGI.sub.2 -mimetic activities, and a TXA.sub.2 antagonist. CGRP, progesterone and some of the nitric oxide substrate and donor compounds are naturally occurring compounds. As such these agents do not have the same toxicity and allergy problems as the foreign substances that are currently used for similar purposes. During pregnancy uterine blood vessels and the uterine muscles are particularly sensitive to CGRP as well as nitric oxide. Therefore, one could administer a very small quantities of these drugs (i.e., intravenously, subcutaneous, or Implants), the effects are then seen mainly in the uterine muscle and blood vessels, namely increase the blood supply to the uteroplacental unit (hence nutrients and oxygen supply to the fetus through the improved placental circulation), and uterine muscular relaxation thereby ameliorate the signs and symptoms of preeclampsia, and eclampsia, and prevent preterm labor. At these dosages, virtually no systemic effects are induced, making CGRP (which is an endogenous natural product present in human body) extremely safe and effective.

    摘要翻译： 本发明提供了一种通过对降钙素基因相关肽（CGRP）或其类似物（包括CGRP /肾上腺髓外素或其基于肽或受体的类似物）进行治疗的怀孕雌性哺乳动物中抵抗先兆子痫，怀孕先兆子痫和早产的方法，或 与孕激素组合，以及有或没有一氧化氮底物或一氧化氮供体或两者，任选地与一种或多种环加氧酶抑制剂，PGI2-模拟物，血栓烷（TXA2）抑制剂，化合物 具有TXA2激动性和TXA2抑制性质，具有TXA2拮抗和PGI2-模拟活性的化合物和TXA2拮抗剂。 CGRP，孕激素和一些一氧化氮底物和供体化合物是天然存在的化合物。 因此，这些试剂与目前用于相似目的的异物不具有相同的毒性和过敏问题。 在怀孕期间，子宫血管和子宫肌肉对CGRP以及一氧化氮特别敏感。 因此，可以施用非常少量的这些药物（即静脉内，皮下或植入物），然后主要在子宫肌肉和血管中观察到这种作用，即增加胎儿胎盘单位的血液供应（因此，营养物质和 通过改善胎盘循环向胎儿提供氧气）和子宫肌肉松弛，从而改善先兆子痫和子痫的体征和症状，并预防早产。 在这些剂量下，几乎没有引起全身作用，使得CGRP（其是人体内存在的内源性天然产物）非常安全和有效。